Australian Clinical Labs Limited (ASX:ACL)

Australia flag Australia · Delayed Price · Currency is AUD
2.770
-0.010 (-0.36%)
Jun 6, 2025, 4:10 PM AEST
23.11%
Market Cap 538.34M
Revenue (ttm) 728.27M
Net Income (ttm) 30.67M
Shares Out 194.35M
EPS (ttm) 0.15
PE Ratio 18.04
Forward PE 14.44
Dividend 0.12 (4.33%)
Ex-Dividend Date Mar 27, 2025
Volume 2,788,708
Average Volume 1,188,199
Open 2.790
Previous Close 2.780
Day's Range 2.730 - 2.810
52-Week Range 2.270 - 3.860
Beta 1.08
RSI 31.75
Earnings Date Aug 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe... [Read more]

Sector Healthcare
Founded 2020
Employees 4,900
Stock Exchange Australian Securities Exchange
Ticker Symbol ACL
Full Company Profile

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.

Financial Statements

News

There is no news available yet.